Literature DB >> 18559556

Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects.

Shaiju K Vareed1, Madhuri Kakarala, Mack T Ruffin, James A Crowell, Daniel P Normolle, Zora Djuric, Dean E Brenner.   

Abstract

BACKGROUND: Curcumin is a polyphenol, found in the spice turmeric, that has promising anticancer properties, but previous studies suggest that absorption of curcumin may be limited.
METHODS: This study examined the pharmacokinetics of a curcumin preparation in healthy human volunteers 0.25 to 72 h after a single oral dose. Curcumin was administered at doses of 10 g (n = 6) and 12 g (n = 6). Subjects were randomly allocated to dose level for a total of six subjects at each dose level. Serum samples were assayed for free curcumin, for its glucuronide, and for its sulfate conjugate. The data were fit to a one-compartment absorption and elimination model.
RESULTS: Using a high-performance liquid chromatography assay with a limit of detection of 50 ng/mL, only one subject had detectable free curcumin at any of the 14 time points assayed, but curcumin glucuronides and sulfates were detected in all subjects. Based on the pharmacokinetic model, the area under the curve for the 10 and 12 g doses was estimated (mean +/- SE) to be 35.33 +/- 3.78 and 26.57 +/- 2.97 mug/mL x h, respectively, whereas C(max) was 2.30 +/- 0.26 and 1.73 +/- 0.19 mug/mL. The T(max) and t(1/2) were estimated to be 3.29 +/- 0.43 and 6.77 +/- 0.83 h. The ratio of glucuronide to sulfate was 1.92:1. The curcumin conjugates were present as either glucuronide or sulfate, not mixed conjugates.
CONCLUSION: Curcumin is absorbed after oral dosing in humans and can be detected as glucuronide and sulfate conjugates in plasma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18559556      PMCID: PMC4138955          DOI: 10.1158/1055-9965.EPI-07-2693

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  48 in total

1.  Glucuronidase deconjugation in inflammation.

Authors:  Kayoko Shimoi; Tsutomu Nakayama
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

2.  Curcuminoids form reactive glucuronides in vitro.

Authors:  Erika Pfeiffer; Simone I Hoehle; Stephan G Walch; Alexander Riess; Anikó M Sólyom; Manfred Metzler
Journal:  J Agric Food Chem       Date:  2007-01-24       Impact factor: 5.279

3.  Induction of cytotoxicity and apoptosis and inhibition of cyclooxygenase-2 gene expression, by curcumin and its analog, alpha-diisoeugenol.

Authors:  Toshiko Atsumi; Yukio Murakami; Kazutoshi Shibuya; Keiichi Tonosaki; Seiichiro Fujisawa
Journal:  Anticancer Res       Date:  2005 Nov-Dec       Impact factor: 2.480

4.  Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.

Authors:  A L Cheng; C H Hsu; J K Lin; M M Hsu; Y F Ho; T S Shen; J Y Ko; J T Lin; B R Lin; W Ming-Shiang; H S Yu; S H Jee; G S Chen; T M Chen; C A Chen; M K Lai; Y S Pu; M H Pan; Y J Wang; C C Tsai; C Y Hsieh
Journal:  Anticancer Res       Date:  2001 Jul-Aug       Impact factor: 2.480

Review 5.  Curcumin: the story so far.

Authors:  R A Sharma; A J Gescher; W P Steward
Journal:  Eur J Cancer       Date:  2005-09       Impact factor: 9.162

Review 6.  "Spicing up" of the immune system by curcumin.

Authors:  Ganesh Chandra Jagetia; Bharat B Aggarwal
Journal:  J Clin Immunol       Date:  2007-01-09       Impact factor: 8.317

7.  Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.

Authors:  Bharat B Aggarwal; Shishir Shishodia; Yasunari Takada; Sanjeev Banerjee; Robert A Newman; Carlos E Bueso-Ramos; Janet E Price
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

8.  Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53.

Authors:  S S Han; S T Chung; D A Robertson; D Ranjan; S Bondada
Journal:  Clin Immunol       Date:  1999-11       Impact factor: 3.969

9.  Glucuronidation of curcuminoids by human microsomal and recombinant UDP-glucuronosyltransferases.

Authors:  Simone I Hoehle; Erika Pfeiffer; Manfred Metzler
Journal:  Mol Nutr Food Res       Date:  2007-08       Impact factor: 5.914

10.  Dose escalation of a curcuminoid formulation.

Authors:  Christopher D Lao; Mack T Ruffin; Daniel Normolle; Dennis D Heath; Sandra I Murray; Joanne M Bailey; Martha E Boggs; James Crowell; Cheryl L Rock; Dean E Brenner
Journal:  BMC Complement Altern Med       Date:  2006-03-17       Impact factor: 3.659

View more
  139 in total

1.  Epigenetic changes induced by curcumin and other natural compounds.

Authors:  Simone Reuter; Subash C Gupta; Byoungduck Park; Ajay Goel; Bharat B Aggarwal
Journal:  Genes Nutr       Date:  2011-04-24       Impact factor: 5.523

2.  Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice.

Authors:  Liu Zhongfa; Ming Chiu; Jiang Wang; Wei Chen; Winston Yen; Patty Fan-Havard; Lisa D Yee; Kenneth K Chan
Journal:  Cancer Chemother Pharmacol       Date:  2011-10-04       Impact factor: 3.333

Review 3.  Curcumin nanoformulations: a future nanomedicine for cancer.

Authors:  Murali M Yallapu; Meena Jaggi; Subhash C Chauhan
Journal:  Drug Discov Today       Date:  2011-09-18       Impact factor: 7.851

4.  Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP.

Authors:  Hiroyuki Kusuhara; Hidetoshi Furuie; Akihiro Inano; Akihiro Sunagawa; Saiko Yamada; Chunyong Wu; Shinya Fukizawa; Nozomi Morimoto; Ichiro Ieiri; Mariko Morishita; Kiminobu Sumita; Hiroshi Mayahara; Takuya Fujita; Kazuya Maeda; Yuichi Sugiyama
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

5.  Curcumin, but not curcumin-glucuronide, inhibits Smad signaling in TGFβ-dependent bone metastatic breast cancer cells and is enriched in bone compared to other tissues.

Authors:  Andrew G Kunihiro; Julia A Brickey; Jennifer B Frye; Paula B Luis; Claus Schneider; Janet L Funk
Journal:  J Nutr Biochem       Date:  2018-10-11       Impact factor: 6.048

6.  Mechanisms of colitis-accelerated colon carcinogenesis and its prevention with the combination of aspirin and curcumin: Transcriptomic analysis using RNA-seq.

Authors:  Yue Guo; Zheng-Yuan Su; Chengyue Zhang; John M Gaspar; Rui Wang; Ronald P Hart; Michael P Verzi; Ah-Ng Tony Kong
Journal:  Biochem Pharmacol       Date:  2017-03-04       Impact factor: 5.858

7.  Curcumin glucuronides: assessing the proliferative activity against human cell lines.

Authors:  Ashutosh Pal; Bokyung Sung; Basvoju A Bhanu Prasad; Paul T Schuber; Sahdeo Prasad; Bharat B Aggarwal; William G Bornmann
Journal:  Bioorg Med Chem       Date:  2013-11-12       Impact factor: 3.641

8.  Determination of androgen receptor degradation enhancer ASC-J9(®) in mouse sera and organs with liquid chromatography tandem mass spectrometry.

Authors:  Shu Fang Soh; Chiung-Kuei Huang; Soo Ok Lee; Defeng Xu; Shuyuan Yeh; Jun Li; Eu Leong Yong; Yinhan Gong; Chawnshang Chang
Journal:  J Pharm Biomed Anal       Date:  2013-08-27       Impact factor: 3.935

Review 9.  Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers.

Authors:  Bharat B Aggarwal; Subash C Gupta; Bokyung Sung
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

10.  Polymeric curcumin nanoparticle pharmacokinetics and metabolism in bile duct cannulated rats.

Authors:  Peng Zou; Lawrence Helson; Anirban Maitra; Stephan T Stern; Scott E McNeil
Journal:  Mol Pharm       Date:  2013-04-22       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.